CoChat
Sign Up
Cited by 121Pancreatic and Hepatic Oncology ResearchPancreatitis Pathology and TreatmentGallbladder and Bile Duct Disorders

Diagnostic strategies for early pancreatic cancer

Open access
Hanada, Keiji, Okazaki, Akihito, Hirano, Naomichi, Izumi, Yoshihiro, Teraoka, Yuji, Ikemoto, Juri, Kanemitsu, Kozue, Hino, Fumiaki +2 more·2015·Journal of Gastroenterology
DOI 10.1007/s00535-014-1026-z
Open this paper in CoChat — free accountOpen PDF

Abstract

Diagnosis of pancreatic cancer (PC) at an early stage with curative surgery is the approach with the potential to significantly improve long-term patient outcome. Recently, some reports showed that patients with pancreatic tumors smaller than 10 mm showed a favorable prognosis. However, the rate of tumor detection on computed tomography in patients with small pancreatic tumors is low. For the diagnoses of PC with tumors smaller than 10 mm, the rate of tumor detection was higher on endoscopic ultrasonography (EUS) than on computed tomography or other modalities, and histologic diagnosis using EUS-guided fine-needle aspiration was helpful in confirming the diagnosis. For the diagnosis of PC in situ, EUS and magnetic resonance cholangiopancreatography may play important roles in detecting the local irregular stenosis of the pancreatic duct. Endoscopic retrograde pancreatography and sequential cytodiagnosis using pancreatic juice obtained by endoscopic nasopancreatic drainage multiple times was useful in the final diagnosis of PC in situ. At present, improving survival lies in identifying those individuals with high-risk factors or precursor lesions through an effective screening method. For example, these should include ultrasonography, various biological markers, or national familial pancreatic cancer registration. Additionally, the relationship between specialists in PC from medical centers and practicing physicians plays an important role in the early diagnosis of PC.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00535-014-1026-z

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 56 · Cited by 121

Research works printed but not linked: 52

  1. Warshaw AL, Ferna ´ndez-del Castillo C. Pancreatic carcinoma. N Engl J Med. 1992;326:455-65.
  2. Rosewicz S, Wiedenmann B. Pancreatic carcinoma. Lancet. 1997;349:485-9.
  3. Furuta K, Watanabe H, Ikeda S. Differences between solid and duct-ectatic type of pancreatic ductal carcinoma. Cancer. 1992; 69:1327-33.
  4. Egawa S, Toma H, Ohigashi H, et al. Japan Pancreatic Cancer Registry; 30th year anniversary. Pancreas. 2012;41:985-92.
  5. Yamaguchi K, Okusaka T, Shimizu K, et al. EBM-based clinical guidelines for pancreatic cancer (2013) issued by the Japan Pancreatic Society: a synopsis. Jpn J Clin Oncol. 2014. doi:10. 1093/jjco/hyu127. · DOI
  6. Uehara H, Nakaizumi A, Ishikawa O, et al. Development of ductal carcinoma of the pancreas during follow-up of branch duct intraductal papillary mucinous neoplasm of the pancreas. Gut. 2008;57:1561-5.
  7. Hanada K, Amano H, Hino F, et al. Management strategies for branch duct intraductal papillary-mucinous neoplasms. Dig En- dosc. 2006;18:S68-72.
  8. Tada M, Kawase T, Arizumi M, et al. Pancreatic cancer in patients with pancreatic cystic lesions: a prospective study in 197 patients. Clin Gastroenterol Hepatol. 2006;4:1265-70.
  9. Maguchi H, Tanno S, Mizuno N, et al. Natural history of branch duct intraductal papillary mucinous neoplasms of the pancreas. Pancreas. 2011;40:364-70.
  10. Yamaguchi K, Kanemitsu S, Hatori T, et al. Pancreatic ductal adenocarcinoma derived from IPMN and pancreatic ductal ade- nocarcinoma concomitant with IPMN. Pancreas. 2011;40:571-80.
  11. Klein AP. Identifying people at a high risk of developing pan- creatic cancer. Nat Rev. 2013;13:66-74.
  12. Canto MI, Goggins M, Yeo CJ, et al. Screening for pancreatic neoplasma in high-risk individuals: an EUS-based approach. Clin Gastroenterol Hepatol. 2004;2:606-21.
  13. Kastrinos F, Fukushima N, Takaori K, et al. Risk of pancreatic cancer in families with Lynch syndrome. JAMA. 2009;302: 1790-5.
  14. Vesen HF, Gruis NA, Frants RR, et al. Risk of developing pan- creatic cancer in families with familiar atypical multiple mole melanoma associated with a specific 19 deletion of p16 (p16 Leiden). Int J Cancer. 2000;87:809-11.
  15. Poley JW, Kluijt I, Gouma DJ, et al. The yield of first-time endoscopic ultrasonography in screening individuals at a high risk of developing pancreatic cancer. Am J Gastroenteol. 2009;104:2175-81.
  16. Riker A, Libutti SK, Bartlett DL. Advances in the early detection, diagnosis, and staging of pancreatic cancer. Surg Oncol. 1997;6:157-69.
  17. Ballehaninna UK, Chamberlain RS. The clinical utility of serum CA19-9 in the diagnosis, prognosis and management of pan- creatic adenocarcimona: an evidence based appraisal. J Gastro- intest Oncol. 2012;3:105-19.
  18. Nishiumi S, Shinohara M, Ikeda A, et al. Serum metabolomics as a novel diagnostic approach for pancreatic cancer. Metabolomics. 2010;6:518-28.
  19. Kobayashi T, Nishiumi S, Ikeda A, et al. A novel serum meta- bolomics-based diagnostic approach to pancreatic cancer. Cancer Epidemiol Biomark Prev. 2013;22:571-9.
  20. Yu J, Li A, Hong SM, et al. MicroRNA alterations of pancreatic intraepithelial neoplasias. Clin Cancer Res. 2012;18:981-92.
  21. Tricoli JV, Jacobson JW. MicroRNA: potential for cancer detection, diagnosis, and prognosis. Cancer Res. 2007;67:4553-5.
  22. Mori Y, Ohtsuka T, Kono H, et al. A minimally invasive and simple screening test for detection of pancreatic ductal adeno- carcinoma using biomarkers in duodenal juice. Pancreas. 2013;42:187-92.
  23. Canto MI, Goggins M, Hruban RH, et al. Screening for early pancreatic neoplasia in high-risk individuals: a prospective con- trolled study. Clin Gastroenterol Hepatol. 2006;4:766-81.
  24. Kamata K, Kitano M, Kudo S, et al. Value of EUS in early detection of pancreatic ductal adenocarcinomas in patients with intraductal papillary mucinous neoplasms. Endoscopy. 2014;46: 22-9.
  25. Tanaka S, Nakao M, Ioka T, et al. Slight dilatation of the main pancreatic duct and presence of pancreatic cysts as predictive signs of pancreatic cancer: a prospective study. Radiology. 2010; 254:965-72.
  26. Hanada K, Iiboshi T, Hirano N, et al. Role of EUS for small pancreatic cancer less than 1 cm. Tan Sui. 2009;30:343-8 (In Japanese).
  27. Sakamoto H, Kitano M, Takeyama Y, et al. Early diagnosis of pancreatic cancer: approach to the diagnosis of very small pan- creatic cancer with emphasis of US, MDCT and EUS. Tan Sui. 2009;30:335-41 (In Japanese).
  28. Hijioka S, Ikari T, Kamei A, et al. CT and MRI findings with contrast enhancement of small pancreatic adenocarcinoma in the late phase. Hepatogastroenterology. 2007;54:389-92.
  29. Serrano OK, Chaudhry MA, Leach SD, et al. The role of PET scanning in pancreatic cancer. Adv Surg. 2010;44:313-25.
  30. Okano K, Kakinoki K, Akamoto S, et al. 18F-fluorodeoxyglucose positron emission tomography in the diagnosis of small pancre- atic cancer. World J Gastroenterol. 2011;17:231-5.
  31. Seo S, Doi R, Machimoto T, et al. Contribution of 18F-fluoro- deoxyglucose positron emission tomography to the diagnosis of early pancreatic carcinoma. J Hepatobiliary Pancreat Surg. 2008;15:634-9.
  32. Matsumoto I, Shirakawa S, Shinzeki M, et al. 18F-fluorodeoxy- glucose positron emission tomography does not aid in diagnosis of pancreatic ductal adenocarcinoma. Clin Gastroenterol Hepatol. 2013;11:712-8.
  33. Maguchi H. The roles of endoscopic ultrasonography in the diagnosis of pancreatic tumors. J Hepatobilbiliary Pancreat Surg. 2004;11:1-3.
  34. Irisawa A, Sato A, Ikeda T, et al. Early diagnosis of small pan- creatic cancer: role of endoscopic ultrasonography. Dig Endosc. 2009;21:S92-6.
  35. Kimmey MB, Bronner MP, Byrd DR, et al. Screening and sur- veillance for hereditary pancreatic cancer. Gastrointest Endosc. 2002;56:S82-6.
  36. Geenhalf W, Neoptolemos JP. Increasing survival rates of patients with pancreatic cancer by earlier identification. Nat Clin Pract Oncol. 2006;3:346-7.
  37. Uehara H, Ikezawa K, Kawada N, et al. Diagnostic accuracy of endoscopic ultrasound-guided fine needle aspiration for suspected pancreatic malignancy in relation to the size of lesions. J Gas- troenterol Hepatol. 2011;26:1256-61.
  38. Takagi T, Irisawa A, Sawaki A, et al. Effectiveness of EUS-FNA for the diagnosis of small pancreatic cancer less than 10 mm. Tan Sui. 2009;30:361-7 (In Japanese).
  39. Yokohata K, Shirahane H, Yonemasu T, et al. Focal ductal branch on magnetic resonance cholangiopancreatography: a hint for early diagnosis of pancreatic carcinoma. Scand J Gastroen- terol. 2000;11:1229-32.
  40. Hanada K, Iiboshi T, Yamao K, et al. Diagnostic strategies for the early diagnosis of pancreatic cancer. Gastroenterol Endosc. 2012;54:3773-82 (In Japanese with English abstract).
  41. Seki M, Ninomiya E, Takano K, et al. Pancreatogram findings for carcinoma in situ (CIS) of the pancreas seen on endoscopic ret- rograde cholangiopancreatography and postoperative pancrea- tography of resected specimens: can CIS be diagnosed preoperatively? Pancreatology. 2008;8:142-52.
  42. Ikeda S, Maeshiro K, Ryu S, et al. Diagnosis of small pancreatic cancer by endoscopic balloon-catheter spot pancreatography. Pancreas. 2009;38:e102-13.
  43. Brune K, Abe T, Canto M, et al. Multifocal neoplastic precursor lesions associated with lobular atrophy of the pancreas having a strong family history of pancreatic cancer. Am J Surg Pathol. 2006;30:1067-76.
  44. Iiboshi T, Hanada K, Fukuda T, et al. Value of cytodiagnosis using endoscopic nasopancreatic drainage for early diagnosis of pancreatic cancer. Pancreas. 2012;41:523-9.
  45. Takaori K, Matsusue S, Fujikawa T, et al. Carcinoma in situ of the pancreas associated with localized fibrosis: a clue to early detection of neoplastic lesions arising from pancreatic ducts. Pancreas. 1998;17:102-5.
  46. Nakaizumi A, Tatsuta M, Uehara H, et al. Cytologic examination of pure pancreatic juice in the diagnosis of pancreatic carcinoma. The endoscopic retrograde intraductal catheter aspiration cyto- logic technique. Cancer. 1992;70:2610-4.
  47. Nakaizumi A, Tatsuta M, Uehara H, et al. Effectiveness of the cytologic examination of pure pancreatic juice in the diagnosis of early neoplasia of the pancreas. Cancer. 1995;76:750-7.
  48. Mikata R, Ishihara T, Tada M, et al. Clinical usefulness of repeated pancreatic juice cytology via endoscopic naso-pancre- atic drainage tube in patients with pancreatic cancer. J Gastroen- terol. 2012;48:866-73.
  49. Kimura K, Furukawa Y, Yamasaki S, et al. A study of the useful- ness of pancreatic juice cytology obtained via an endoscopic nasal pancreatic drainage (ENPD) tube. Nihon Shokakibyo Gakkai Zasshi. 2011;108:928-36 (In Japanese with English abstract).
  50. Hanada K, Iiboshi T, Hirano N, et al. A social program for diagnosis of the stage 0 pancreatic cancer in a rural doctor's association. Pancreas. 2012;41:1156.
  51. Hanada K, Iiboshi T. Recent advances in the early diagnosis of pancreatic cancer. Nihon Shokakibyo Gakkai Zasshi. 2013;110:2051-9 (In Japanese).
  52. Fukasawa M, Yoda Y, Takayama I, et al. Regional cooperation aimed at the early detection of pancreatic cancer. Kan Tan Sui. 2013;66:277-84 (In Japanese).

Authors
Hanada, K., Okazaki, A., Hirano, N., Izumi, Y., Teraoka, Y., Ikemoto, J., Kanemitsu, K., Hino, F., Fukuda, T., & Yonehara, S.
Affiliations
Onomichi General Hospital (JP)
Corresponding author
Hanada, Keiji
ORCID
Venue
Journal of Gastroenterology
Publisher
Springer Science and Business Media LLC
Published
2014-12-14
Volume
50
Issue
2
Pages
147-154
ISSN
  • 0944-1174 (ISSN-L)
  • 1435-5922
DOI
10.1007/s00535-014-1026-z
OpenAlex
W2020863886
Cited by
121
References
56
Citations by year
2026: 5 · 2025: 6 · 2024: 11 · 2023: 9 · 2022: 11 · 2021: 18 · 2020: 8 · 2019: 14 · 2018: 18 · 2017: 11 · 2016: 4 · 2015: 6
FWCI
0.80
Type
journal article
Language
en
Open access
Licence
www.springer.com/tdm (tdm)
Locations
  • Journal of Gastroenterology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
  • Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Gallbladder and Bile Duct Disorders
Keywords
early-stage pancreatic cancer, pancreatic cancer diagnosis, endoscopic ultrasound, endoscopic ultrasound-guided fine-needle aspiration, magnetic resonance cholangiopancreatography, endoscopic retrograde pancreatography, pancreatic duct stenosis, pancreatic cancer screening, precursor lesions, tumor size
MeSH terms
Carcinoma in Situ, Humans, Interprofessional Relations, Pancreatic Neoplasms, Risk Factors, Endosonography, Early Diagnosis, Early Detection of Cancer

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review